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Introduction
T cell–directed immunotherapy has delivered remarkable therapeutic benefits in cancer patients. For example, 
the use of  function-blocking antibodies to immune checkpoints programmed death 1 (PD-1) and cytotoxic T 
lymphocyte antigen 4 (CTLA-4) has proven efficacious in otherwise untreatable and aggressive cancers, such 
as malignant melanoma (1–3). Nonetheless, checkpoint inhibition induces complete and durable therapeutic 
responses in only a small minority of  patients and is completely dependent on the existence and functional-
ity of  preexisting tumor-reactive host T cells. Adoptive cell transfer of  genetically engineered tumor-reactive 
T cells has long been touted as an alternative approach to cure and provide long-lasting protection from 
the reoccurrence of  cancer (4, 5). Indeed, CD19-directed chimeric antigen receptor (CAR) T cell therapy is 
effective in curing otherwise intractable acute lymphoblastic lymphoma in up to 90% of pediatric patients (6). 
However, the toxicity associated with CAR T cell therapies means that there are substantial hurdles to over-
come to improve the safety and wider applicability of  these approaches in the clinic (7).
Potential alternatives to CAR T cell therapy include infusion of  patients with autologous ex vivo–
expanded tumor-infiltrating lymphocytes or T cells engineered to express tumor antigen-specific conven-
tional T cell receptors (TCR). Furthermore, genetic manipulation of  T cells to influence effector function, 
longevity, and metabolic capacity can be combined with expression of  tumor-reactive TCRs to improve the 
outcome of  such approaches. Previously, we determined that CD8+ T cells lacking the autoimmunity-as-
sociated inhibitory tyrosine phosphatase PTPN22 had enhanced capacity to clear tumors in mice (8, 9). 
The enhanced antitumor responses of  PTPN22-deficient T cells were associated with elevated reactivity to 
low-affinity tumor antigens and a decreased susceptibility to inhibition by tumor-derived TGF-β (8).
A key consideration for ACT approaches to cancer therapy is to determine which T cell phenotype 
provides optimal long-lived protection. Consensus is emerging that terminally differentiated effector T cells 
provide only short-lived protection in cancer models (10–12). The role of  PTPN22 in regulating memory 
T cell responses to tumors is unknown. In the current work, we show that, while Ptpn22–/– effector CTLs 
provide enhanced protection against tumors expressing very low-affinity antigens, neither the control nor 
the Ptpn22–/– effector T cells persist in vivo. By contrast, control and Ptpn22–/– memory phenotype CD8+ T 
cells were similarly long lived upon ACT. Increased longevity of  control and Ptpn22–/– memory phenotype 
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cells was associated with altered cellular metabolism, including enhanced mitochondrial spare respiratory 
capacity (SRC) and decreased glycolytic flux, compared with effector T cells. Importantly, upon transfer to 
naive recipient mice, very low numbers of  long-lived Ptpn22–/– memory T cells provided enhanced protec-
tion from tumor challenge, as compared with control cells. Strikingly, Ptpn22–/–, but not control, memory 
phenotype T cell ACT could completely protect mice from low-affinity antigen-bearing tumors when trans-
ferred to hosts 2–4 weeks prior to tumor implantation. Together, these experiments have determined that 
deletion of  PTPN22 represents a rational approach to enhance the functional capacity of  both short-lived 
effector and long-lived memory T cells in antitumor immunity.
Results
Ptpn22–/– CTLs mediate enhanced clearance of  low-affinity tumors. CD8+ T cells mediate anticancer responses 
directly, by targeting and killing malignant cells, or indirectly, through the production of  inflammatory 
cytokines (13). Our previous experiments determined an enhanced capacity of  Ptpn22–/– CD8+ T cells to 
produce IFN-γ and TNF in response to low-affinity peptide antigens (14, 15) and mediate tumor rejec-
tion upon ACT (8). We sought to determine the effect of  PTPN22 deficiency on the capacity of  CTLs to 
directly mediate target cell killing in response to strong and weak tumor-associated antigens (TAAs). The 
OVA-specific H2-Kb–restricted OT-1 TCR transgenic system has been used extensively to investigate the 
effect of  antigen affinity on T cell selection in the thymus and effector T cell responses (16–18). Control and 
Ptpn22–/– OT-1 T cells were activated with cognate SIINFEKL (N4) peptide for 2 days and then expanded 
and differentiated in a high dose of  IL-2 for 4 days to generate inflammatory effector CTLs. ID8 ovarian 
carcinoma cells (19) expressing high-affinity N4 (KD for OT-1 TCR = 54 μM; ref. 17) or very low-affinity 
SIIVFEKL (V4; KD > 1 mM) OVA variants were used as targets cells. Control and Ptpn22
–/– CTLs were 
equally effective in killing high-affinity ID8-N4 tumor cells (Figure 1A). By contrast, low-affinity ID8-V4 
targets were killed much more efficiently by Ptpn22–/– CTLs as compared with control CTLs (Figure 1A). 
Consistent with the results of  in vitro killing assays, control CTL ACT was sufficient to mediate a signifi-
cant reduction in tumor burden in recipient mice bearing established high-affinity ID8-N4 but not low-af-
finity ID8-V4 intraperitoneal tumors (Figure 1B). Importantly, Ptpn22–/– effector CTL ACT enabled tumor 
clearance in response to both strong N4 and very weak V4 TAAs (Figure 1B). Previous studies have shown 
that TCR triggering influences expression of  inhibitory phosphatases (15); thus, it was of  interest to deter-
mine the levels of  PTPN22 following stimulation of  OT-1 T cells with weak and strong agonist peptides. 
Western blot analysis showed that levels of  PTPN22 expression were elevated following stimulation of  
cells with high-affinity N4 as compared with low-affinity SIITFEKL (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.127847DS1).
Memory phenotype, but not effector CTLs, persist after tumor clearance in vivo. To determine the longevity of  
effector CTLs following tumor clearance in vivo, we cotransferred control and PTPN22-deficient cells to 
transgenic C57BL/6-Ubc-GFP recipient mice bearing high-affinity EL4-OVA s.c. lymphomas. Ubc-GFP 
mice have ubiquitous transgenic expression of  GFP (20), enabling GFP– donor T cells to be easily distin-
guished from host T cells. When assessed 3 weeks after transfer, GFP– donor CTLs could not be reliably 
detected in lymph nodes of  Ubc-GFP recipient mice (Figure 2A). Previous studies have defined a critical role 
for CD28 costimulation during T cell priming for the formation of  long-lived memory T cell populations (21). 
Furthermore, in vitro culture in the presence of  IL-15, rather than IL-2, favors the differentiation of  memory 
phenotype CD8+ T cells (22). Therefore, we incorporated CD28 costimulation and IL-15 culture into our in 
vitro differentiation model to generate memory phenotype OT-1 T cells for ACT to EL4-OVA tumor-bearing 
mice. Importantly, and in contrast to effector CTLs, control memory phenotype OT-1 T cells were readily 
detectable 3 weeks after transfer in lymph nodes of  Ubc-GFP host mice (Figure 2A). Cotransfer experiments 
were performed to compare the ability of  control Ly5.1+ and Ptpn22–/– Ly5.2+ memory phenotype CD8+ T 
cells to persist in tumor-bearing hosts. Cotransfer of  memory phenotype control and Ptpn22–/– CD8+ cells 
cleared s.c. EL4-OVA tumors, while the ratio of  Ly5.1+/Ly5.2+ donor cells in lymph nodes and at the tumor 
site (skin) was assessed weekly by ex vivo FACS analysis (Figure 2, B and C). The results showed that the ratio 
of  control/Ptpn22–/– T cells remained approximately 1:1 for the duration of  the experiment, indicating that 
PTPN22 deficiency does not impinge on T cell survival and longevity following tumor clearance.
PTPN22 limits cytokine production and target cell killing of  memory phenotype T cells. Our data indicated that 
PTPN22 did not adversely influence T cell memory formation following ACT. Further experiments were 
undertaken to define the consequence of  PTPN22 deficiency on the functional capacities of  memory phe-
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notype T cells. Intracellular staining and FACS analysis demonstrated that, as compared with memory phe-
notype cells, effector phenotype T cells typically expressed lower levels of  CD62L and higher levels of  cell 
surface receptors CD25, CD44, CD69, and CD71; transcription factors Tbet, Eomesodermin, and IRF4; 
and cytolytic effector protein granzyme B (Supplemental Figure 2). However, Ptpn22 deficiency did not effect 
expression of  these proteins in either effector or memory CD8+ T cell populations (Supplemental Figure 
2). However, restimulation of  memory phenotype OT-1 T cells and analysis of  IFN-γ and TNF production 
revealed a striking difference in the capacity of  PTPN22-deficient cells to respond to low-affinity OVA-T4 
peptide (KD = 444 μM; ref. 17) but not OVA-N4 (Figure 3, A and B). Furthermore, while control and Ptpn22
–/– 
memory phenotype T cells were effective in killing high-affinity ID8-N4 targets in vitro, Ptpn22–/– cells had a 
markedly improved capacity to kill low-affinity ID8-T4 cells (Figure 3C). Therefore, and similar to the case for 
effector CTLs, PTPN22 limits the functional capacity of  memory phenotype CD8+ T cells in vitro.
A wealth of  data have indicated that the regulation of  cellular metabolic pathways is key to establishing 
T cell phenotype. Previous studies determined that memory T cells have enhanced mitochondrial SRC and 
reduced glycolytic flux as compared with effector T cells (21, 23). Our data indicated that both effector and 
memory phenotype T cell functional capacity (cytokine production and killing capacity) were negatively 
regulated by PTPN22; therefore, we wished to test whether these phenotypes were associated with altered 
cellular metabolism. Uptake of  the fluorescent glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ami-
no)-2-deoxyglucose (2-NBDG) by in vitro–generated effector OT-1 CTLs was substantially higher than 
that of  memory phenotype OT-1 cells (Figure 4A). However, PTPN22 deficiency did not effect 2-NBDG 
uptake in either cell population. Analysis of  oxygen consumption rate (OCR) using a Seahorse XFe96 
Analyzer showed that PTPN22 deficiency did not affect SRC (Figure 4B) or mitochondrial metabolism in 
either memory phenotype (Figure 4C) or effector (Figure 4D) OT-1 T cells. Furthermore, basal glycolytic 
flux, as assessed by extracellular acidification rate (ECAR), was similar for control and Ptpn22–/– memory 
phenotype OT-1 T cells (Figure 4B). Therefore, PTPN22 deficiency does not impinge upon the 2 major 
ATP-producing pathways in effector or memory phenotype T cells.
Figure 1. Effector CTLs deficient in PTPN22 kill tumor cells expressing low-affinity antigen more efficiently. (A) Effector control and Ptpn22–/– OT1 CTLs 
were assessed for their capacity to kill target ID8-fLuc cells expressing high- (N4) or extremely low-affinity (V4) antigen in an in vitro killing assay. ID8 cell 
death was measured by a decrease in luminescence, as assessed by IVIS. Graphs show the percentage specific lysis at various effector-to-target ratios. 
Control and Ptpn22–/– CTLs were both able to effectively kill ID8-N4-fLuc cells, whereas Ptpn22–/– CTLs were more effective than control CTLs at killing 
ID8-V4-fLuc targets. **P < 0.01, as determined by 2-way ANOVA. Effector, CTLs; targets, ID8 cells. (B) Groups (n = 7) of C57BL/6J mice were injected i.p. 
with 5 × 106 ID8-N4-fLuc or ID8-V4-fLuc and assessed for tumor establishment on day 5 (pretreatment) by bioluminescence imaging. On day 6, groups of 
mice received no cells or 1 × 107 effector control or Ptpn22–/– OT1 CTLs i.p. Graphs show the bioluminescence signal intensity of all mice on day 5 (1 day prior 
to ACT) and day 18 (12 days after ACT). Both control and Ptpn22–/– CTLs were able to suppress growth of ID8-N4 tumors, while only Ptpn22–/– CTLs could 
significantly suppress the establishment of ID8-V4 tumors. *P < 0.05, **P < 0.01, ***P < 0.001, as determined by Student’s paired t test.
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PTPN22 deficiency improves memory T cell–mediated tumor clearance. In order to test whether PTPN22 defi-
ciency in memory T cells afforded protection against tumors in vivo, we used a serial ACT approach (Fig-
ure 5A). Ubc-GFP mice were injected with s.c. EL4-OVA lymphoma cells and then infused i.v. with large 
numbers (i.e., 107) of  control or Ptpn22–/– memory phenotype OT-1 T cells, which were sufficient to clear 
the primary tumor (Supplemental Figure 3). Following 21–28 days, long-lived memory OT-1 T cells were 
phenotyped ex vivo. The majority of  both control (~80%) and Ptpn22–/– (~70%) OT-1 T cells had a CD44hiC-
D62Lhi central memory–like (Tcm-like) phenotype (Figure 5B). There was a nonsignificant trend toward an 
elevated proportion of  Ptpn22–/– cells having a CD44hiCD62Llow effector memory phenotype (Figure 5B). 
Restimulation with low-affinity OVA-T4 variant peptides revealed enhanced IFN-γ and TNF production by 
PTPN22-deficient cells (Figure 5, C and D), consistent with the phenotype of  cells prior to ACT (Figure 
3C). Furthermore, memory OT-1 T cells were FACS sorted to high purity and adoptively transferred i.v. to 
C57BL/6J hosts. Groups of  mice were challenged with s.c. EL4-OVA cells and tumor mass was assessed as 
wet weight at experimental endpoints. Strikingly, low numbers (i.e., 104) of  adoptively transferred Ptpn22–/–, 
but not control, memory T cells significantly reduced tumor burden in recipient mice (Figure 5, E and F).
We tested the ability of control and Ptpn22–/– memory T cell to mediate protection against low-affinity 
tumors in vivo. Control or Ptpn22–/– memory phenotype T cells were transferred to host mice, and, following 
engraftment for 24 days, hosts were challenged with OVA-T4–bearing EL4 tumors (Figure 6A). Hosts receiving 
either no ACT or control T cell ACT developed tumors at a similar rate (Figure 6B) and of a similar size (Figure 
6C). Remarkably, ACT of Ptpn22–/– memory phenotype T cells, 24 days prior to tumor challenge, completely 
prevented the development of EL4-OVA-T4 tumors in 100% of mice tested (Figure 6, B and C, 13 of 13 mice in 
2 experiments). Finally, we tested the longevity of protection afforded by ACT of Ptpn22–/– memory phenotype 
cells. Whereas hosts receiving either no ACT or control ACT succumbed to OVA-T4–bearing tumors within 12 
days after challenge, mice (n = 7) receiving Ptpn22–/– memory phenotype cells remained entirely tumor free for 
at least 90 days following tumor cell injection (Figure 6D). Flow cytometry analysis of host lymph nodes and 
spleens determined that a population of transferred central memory phenotype Ptpn22–/– CD8+CD44hiCD62L+ 
T cells could be detected at the experimental endpoint (day 90 after tumor challenge and day 104 after ACT) (Fig-
ure 6, E and F). Together, these data indicate that PTPN22-deficient CD8+ memory T cells retain their enhanced 
functional characteristics and are superior in their capacity to provide long-lived protection from tumor growth 
in response to both high- and low-affinity tumor antigens in vivo, as compared with control T cells.
Figure 2. Ptpn22 does not effect the increased survival of memory versus effector CTLs in vivo. (A) On day 0, groups 
(n = 5) of C57BL/6 UbC-GFP hosts were injected with 1 × 106 EL4-N4 cells s.c. On day 6 after EL4 injection, groups of 
mice were injected with a mix of control and Ptpn22–/– effector CTLs or memory cells i.v. The recovery of these cells 
within LN and spleen populations was assessed 3 weeks after injection (day 27) by FACS, and they were identified as 
GFP-ve, CD8β+ T cells. Example dot plots are shown and dots on the graph represent individual animals. The propor-
tion of donor CTLs recovered within the total CD8+ population was extremely low (<0.5%); in contrast, the proportion 
of memory cells was approximately 10% of total CD8+ T cells. (B and C) C57BL/6 UbC-GFP hosts (n = 10) were injected 
with 1 × 106 EL4-OVA cells s.c. (day = –6). After 6 days all mice were injected with an equal mix of control and Ptpn22–/– 
memory cells (5 × 106 of each) (day = 0), and groups of mice (n = 3/4) were assessed at day 8, day 14, and day 21 after 
memory cell injection by FACS. Example dot pots (from d = 21) are shown (B), and graphs (C) show the proportion of 
recovered control versus Ptpn22–/– memory cells within the LN and skin at the various time points. The ratio of control/
Ptpn22–/– memory cells remains approximately 1:1 throughout the time course.
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Discussion
Effective and long-lived immune protection from malignancies requires both an immediate antitumor effector 
response and maintenance of  a population of  protective memory T cells. In the current study, we have demon-
strated that PTPN22 is a key negative regulator of  both effector and memory T cell responses to tumors. 
Effector and memory phenotype Ptpn22–/– CD8+ T cells have enhanced cytolytic capacity and elevated cyto-
kine production in response to low-affinity TAAs, as compared with control counterparts. Furthermore, long-
lived Ptpn22–/– memory T cells retain their enhanced capacity to control tumor growth in vivo.
A majority of  tumor-associated antigens that have been targeted in the clinic for immunotherapy 
are aberrantly expressed self-antigens (24). These antigens are expressed during development and, as 
a result of  selection processes in the thymus and periphery, the responsive endogenous T cell reper-
toire is limited to cells expressing low-affinity TCRs (25). Expression of  high-affinity CARs enables 
autologous T cells to respond to surface-exposed TAAs but not against intracellular antigens that are 
processed and presented via MHC molecules. Therefore, expression of  conventional TCRs may be 
preferable for T cell ACT in some circumstances. Furthermore, genetic approaches to enhance the 
survival or functionality of  tumor-reactive T cells have the potential to improve the efficacy of  cancer 
immunotherapy. Our previous work identified PTPN22 as a critical regulator of  T cell responses to 
low-affinity antigens (14, 15). PTPN22 inhibits T cell activation by dephosphorylating key TCR-proxi-
mal kinases, including Lck and ZAP70, and, consequently, Ptpn22–/– T cells have a lower threshold for 
activation (9, 26). In the present work, we showed that Ptpn22–/– effector OT-1 CTLs had remarkable 
ability to target and kill ID8 ovarian carcinomas cells expressing the very low-affinity V4 OVA variant 
both in vitro and in vivo. However, and consistent with previous studies, both control and Ptpn22–/– 
effector CTLs were short lived in vivo.
It is generally held that ACT using fully differentiated effector CD8+ T cells is inferior to the trans-
fer of  memory phenotype T cells for the eradication of  tumors (10, 12). It is thought that this phenom-
enon is related to a reduced capacity of  effector T cells to self-renew and survive in vivo. In addition, 
chronic stimulation of  effector T cells by TAAs can lead to functional exhaustion (27). Interestingly, 
studies showed that PTPN22 deficiency prevented T cell exhaustion in chronic viral infection in mice 
(28, 29). However, this was predominantly through a cell-extrinsic mechanism as a consequence of  
Figure 3. Ptpn22 deficiency improves cytokine production and killing capacity in memory cells stimulated with weak affinity antigens. Control 
and Ptpn22–/– memory phenotype cells were generated in vitro for 6 days before phenotypic and functional analysis. Control and Ptpn22–/– memory 
cells were restimulated with varying concentrations of high-affinity (N4) and low-affinity (T4) peptide for 4 hours before intracellular staining for IFN 
and TNF. Dots on the graphs show the frequency of IFN-γ+ (A) and TNF+ (B) cells within the population of memory cells generated from 3 individual 
mice. (C) Control and Ptpn22–/– memory phenotype cells were assessed for their capacity to kill target ID8-fLuc cells expressing high- (N4) or low-af-
finity (T4) antigen in an in vitro killing assay. ID8-fLuc cell death was measured by a decrease in luminescence, as assessed by IVIS. Graphs show the 
percentage specific lysis at various effector-to-target ratios. Ptpn22 deficiency increases the killing capacity and frequency of IFN-γ+ and TNF+ cells 
upon restimulation in response to weak affinity antigens. Effector, CTLs; targets, ID8 cells. **P < 0.01, ***P < 0.001, as determined by 2-way ANOVA.
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reduced type I IFN production by myeloid cells. By limiting PTPN22 deficiency solely to T cells in 
the current study, cotransfer experiments showed that control and Ptpn22–/– memory phenotype OT-1 
T cells had a similar capacity to form long-lived memory cells upon ACT to tumor-bearing recipients. 
Most importantly, the enhanced functional capacity of  Ptpn22–/– memory T cells was retained, as evi-
denced by an improved antitumor response upon transfer to a secondary host. In the current work, 
we investigated memory cell retention following clearances of  tumors expressing high-affinity TAAs. 
The choice of  a high-affinity TAA was to ensure that control and Ptpn22–/– CD8+ T cells were similarly 
capable of  clearing the primary tumor. Using primary tumors expressing a weak TAA complicated 
analysis of  memory cell formation, as we consistently found that ACT of  Ptpn22–/– cells was substan-
tially superior to control ACT in mediating tumor clearance. Nonetheless, we showed that ACT of  
Ptpn22–/– but not control memory phenotype T cells 14–24 days prior to tumor inoculation completely 
prevented growth of  low-affinity EL4-OVA-T4 tumors. Protection afforded by Ptpn22–/– T cells was 
sustained for at least 3 months, while a population of  Ptpn22–/– T cells could be recovered from hosts 
for at least 104 days after ACT, indicating the longevity of  this population. Therefore, as compared 
with control cells, long-lived Ptpn22–/– T cells have superior antitumor activity in response to both high- 
and low-affinity TAA in vivo.
It is worthy of  note that, in our experiments, we did not perform lymphodepletion prior to memory 
T cell ACT. Host lymphodepletion enhances engraftment of  transferred T cells and is associated with 
favorable ACT therapy outcomes (30, 31) but may cause immune dysfunction (32). Given that we showed 
previously that, in profoundly lymphopenic environments, Ptpn22–/– T cells expanded to a greater extent 
than cotransferred control cells, we did not want to confound the data by lymphodepleting the hosts (14). 
Despite entering a lymphoreplete host, Ptpn22–/– memory cells were clearly able to establish themselves and 
maintain long-term antitumor protection.
In the past decade, numerous studies have determined that T cell activation and differentiation are 
linked to the regulation of  cell metabolism (33). Effector T cells rely on engagement of  aerobic glycoly-
sis (34), whereas memory T cells typically use fatty acid oxidation and oxidative phosphorylation (35). 
We determined that, in our system, memory phenotype OT-1 T cells had enhanced mitochondrial 
SRC but decreased glucose uptake and glycolytic flux as compared with effector CTLs, consistent with 
previous literature (21). PTPN22 deficiency did not have a major effect on the engagement of  either 
OXPHOS or glycolytic pathways in either effector or memory phenotype cells. It is worth emphasiz-
Figure 4. Effector and memory phenotype CTLs have distinct metabolic profiles, but PTPN22 does not effect these. 
Effector and memory phenotype OT-1 cells were differentiated for 6 days. On day6, glucose uptake was assessed using 
fluorescent NB-d-glucose (NBDG) and FACS. Effector CTL had higher uptake than memory phenotype cells (A), but 
there was no difference between control and Ptpn22–/– cells. Mitostress test Seahorse analyses were performed (B–D). 
Analysis of spare respiratory capacity (maximal stressed OCR – basal OCR) and basal ECAR (i.e., glycolysis) showed 
similar profiles for control and Ptpn22–/– memory phenotype cells (B). Full Seahorse profiles for memory (C) and effector 
(D) CTLs show no effect of PTPN22 deficiency on OXPHOS. NS, not significant; as determined using Student’s t test.
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Figure 5. PTPN22 deficiency improves T cell memory to tumors. (A) Scheme of experimental design. (B) Groups of 
C57BL/6-UbC-GFP hosts were injected with 1 × 106 EL4-N4 s.c. (day 0) before transfer of 5 × 106 control or Ptpn22–/– 
memory cells i.v. on day 5. On day 29, LNs were harvested from animals and the proportion of central memory 
(TCM: CD44+CD62L+) and effector memory (TEM: CD44+CD62L–) cells within the population of recovered memory 
cells (CD8β+GFP–) was quantified by FACS. (C and D) LN cells were also restimulated with varying concentrations of 
high-affinity (N4) and low-affinity (T4) peptide for 4 hours before intracellular staining for IFN-γ and TNF. Dots on 
the graphs show the frequency of IFN-γ+ and TNF+ cells within the population of recovered memory cells (day 29) 
(CD8β+GFP–). (E and F) Groups (n = 5) of C57BL6-UbC-GFP hosts were injected with 1 × 106 EL4-N4 s.c. before being 
injected with 5 × 106 control or Ptpn22–/– memory phenotype cells i.v. on day 5. On day 28, LNs and spleens were col-
lected, and memory OT-1 cells were sorted by FACS (CD8β+, CD44+, GFP–). 1 × 104 sorted control or Ptpn22–/– cells were 
transferred i.v. into additional groups of C57BL/6-UbC-GFP hosts (day 28), which were injected with 1 × 106 EL4-N4 
the subsequent day (day 29). Control mice received no memory cell ACT. Tumor growth was monitored by caliper 
measurement, as shown for individual mice from 1 experiment (E), and tumor weight was measured at the end of 
the experiment (day 12 after EL4-N4 injection). Each dot represents an individual mouse and represents data from 
3 pooled experiments (F). *P < 0.05, **P < 0.01, ***P < 0.001, as determined by Student’s t test (B and D) or 1-way 
ANOVA with Tukey’s multiple comparisons test (F).
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ing that the differentiation of  OT-1 T cells in our experiments was driven by initial stimulation with 
high-affinity N4 peptide followed by extended culture in high doses of  either IL-2 or IL-15. Impor-
tantly, PTPN22 does not regulate IL-2 or IL-15 receptor signaling directly. It remains possible that 
PTPN22 deficiency affects TCR-driven metabolic reprogramming, but this effect is most likely to be 
apparent upon stimulation with weak agonist peptides (14).
In summary, our work has shown that PTPN22 is a key negative regulator of  antitumor T cell 
responses. The major effect of  PTPN22 deficiency is to endow both effector and memory phenotype 
CD8+ T cells with an enhanced capacity to produce inflammatory cytokines and kill tumors expressing 
low-affinity TAA. Furthermore, as we reported previously, the elevated sensitivity of  Ptpn22–/– cells to 
TCR triggering  may also indirectly affect responses to inhibitory cytokines, such as TGF-β (8). These 
data provide a strong rationale for targeting PTPN22 expression in T cells for ACT in patients in future 
studies.
Figure 6. PTPN22-deficient memory T cells prevent growth of tumors expressing weak antigen. (A) Scheme of 
experimental design. (B) Groups of C57BL/6J hosts were injected with 10 × 106 in vitro–generated control or Ptpn22–/– 
memory cells i.v. on day 0. On day 24, 1 × 106 EL4 cells loaded with T4 peptide were injected i.v. Tumor growth 
was monitored by caliper measurement, as shown for individual mice from 1 experiment (B), and tumor weight 
was measured at the end of the experiment (day 9 after EL4-T4 injection, when tumors in control mice reached a 
maximum-allowed diameter of 15 mm) (C). Each dot represents an individual mouse from 2 repeated experiments 
(C). ****P < 0.0001, as determined by 1-way ANOVA with Tukey’s multiple comparison test. (D) Groups of C57BL/6J 
hosts (n = 7/group) were injected with 10 × 106 in vitro–generated control or Ptpn22–/– memory cells i.v. on day 0. 
Fourteen days after T cell ACT, 1 × 106 EL4 cells loaded with T4 peptide were injected s.c. Tumor growth was moni-
tored by caliper measurement at least 2 times a week for up 90 days after EL4-T4 injection. When tumor diameter 
exceeded 10 mm, mice were removed from the study. ***P < 0.0001, as determined by χ2 and log-rank test. (E and F) 
LNs and spleens were removed from all mice that had received Ptpn22–/– T memory cells at the end of the study (day 
90 after EL4-T4 injection) and assessed for the presence of transferred T cells by FACS. Representative dot plots 
shows the percentage of Ptpn22–/– T memory cells (CD8+CD45.1+CD45.2+) and expression of CD62L and CD44. (F) Dots 
on the corresponding graphs represent values from individual animals.
 
9insight.jci.org   https://doi.org/10.1172/jci.insight.127847
R E S E A R C H  A R T I C L E
Methods
Mice. OT-1 Ly5.1 Rag1–/–, Ptpn22–/– OT-1 Ly5.2 Rag1–/–, Ptpn22 –/– OT-1 Ly5.2+/–Ly5.1+/–Rag1–/–Ubc-GFP, 
and C57BL/6J mice were maintained under specific pathogen–free conditions at the St. James’s Biomedi-
cal Services animal facility at the University of  Leeds. Mice were age and sex matched for all experiments. 
In tumor experiments, recipient mice were randomly assigned to experimental groups. Where applicable, 
group sizes are indicated by individual data points.
In vitro T cell differentiation. For generation of  effector CTLs, lymph node OT-1 T cells were stimulated 
with N4 peptide (Cambridge Peptides) (1 nM) for 2 days in IMDM (Gibco) containing 5% FCS, L-gluta-
mine, antibiotics (penicillin/streptomycin; Gibco), and 50 μM 2-mercaptoethanol. Cells were washed and 
then expanded and differentiated in the presence of  human IL-2 (Peprotech, 20 ng/ml) for a further 4 days. 
For memory T cell differentiation, anti-CD28 (clone 37.51, BioLegend, 1 μg/mL) was added to culture 
media during initial N4 stimulation. Cells were differentiated in IL-2 for 2 days and then switched to IL-15 
(Peprotech, 20 ng/ml) containing IMDM for the final 2 days of  culture.
Cell lines and tumor models. ID8 ovarian carcinoma cells expressing OVA variants N4, T4, and V4 were 
obtained from Dietmar Zehn (Technical University of  Munich, Munich, Germany). Firefly luciferase 
constructs were introduced by lentiviral transduction, as previously described (8). EL4-OVA cells were 
obtained from Klaus Okkenhaug (University of  Cambridge, Cambridge, United Kingdom). Cells were 
maintained in IMDM containing 5% FCS. EL4-OVA cell cultures were supplemented with 400 μg/ml 
G418 antibiotic. In some experiments, parental EL4 cells (a gift of  Alison Taylor, University of  Leeds) 
were cultured overnight with 1 μM T4 peptide and washed 3 times prior to injection. Adherent ID8 cells 
were dissociated from culture flasks using trypsin-EDTA (Gibco). Tumor cell suspensions were prepared 
in PBS (Gibco); EL4-OVA or OVA-T4–loaded parental EL4 cells (1 × 106) were injected s.c. into the right 
dorsal flank, while ID8 cells (5 × 106) were injected intraperitoneally. 3–5 days after tumor cell injection 
mice were randomly divided into 3 groups. Control groups received no ACT, while in vitro–generated 
control or Ptpn22–/– T cell populations were inoculated i.v., as described in individual figure legends. EL4/
EL4-OVA tumor mass was assessed by caliper measurements every 2–3 days, until tumors in control mice 
reached a maximal diameter of  15 mm. For long-term survival experiments, mice were removed from the 
experiment when tumors reached 10 mm in diameter. Tumors were resected and wet mass was assessed. 
In ID8 experiments, tumor bioluminescence was assessed by noninvasive IVIS Spectrum imaging and Liv-
ing Image Software (Perkin Elmer). For the serial ACT experiments shown in Figure 5, CD8+ T cells in 
host Ubc-GFP LNs and spleens were enriched 14–21 days after ACT by magnetic bead sorting (Miltenyi 
Biotech). GFP–CD8β+CD44hi control or Ptpn22–/– memory T cells were purified to >98% purity using a 
BD Influx FACS Sorter (BD) and then transferred i.v. to C57BL/6J hosts, prior to tumor cell inoculation.
In vitro cytotoxicity assay. Target ID8 cells were seeded in 48 well plates for 4–6 hours, prior to addition 
of  T cells at ratios indicated in figures. Following overnight culture, plates were gently washed in sterile 
PBS to remove T cells and ID8 cell debris and fresh was IMDM added. Luciferase activity of  remaining 
target cells was assessed by addition of  luciferin to wells and IVIS imaging. Specific cell lysis was calculated 
by comparison of  luminescence values in experimental wells to target-only and blank wells.
Flow cytometry. The following antibodies were used: CD44-APC Cy7 (clone IM7), CD62L-PE (clone 
MEL-14), CD8β-PE Cy7 (clone YTS156.7.7), IFN-γ-AF488 (clone XMG1.2), TNF-PerCP Cy5.5 (clone 
MP6-XT22), Granzyme B-BV421 (clone GB11), Tbet-PE (clone 4B10), CD45.1-AF647 (clone A20), and 
CD45.2-PE (clone 104) (all from BioLegend). Live/dead aqua dye was from Life Technologies. For analysis 
of  intracellular cytokines, memory phenotype OT-1 T cells or ex vivo LN cells from tumor recipient mice 
were restimulated with N4 or T4 peptides at concentrations described in figures, in the presence of  Brefeldin 
A (MilliporeSigma) for 4 hours. Cells were labeled with surface and live/dead stains prior to fixation/perme-
abilization in FoxP3 buffer (eBioscience). In glucose uptake experiments, T cells were cultured in the presence 
of  50 μM 2-NBDG for 1 hour and then washed 3 times in PBS prior to FACS analysis. Samples were acquired 
using an LSRII flow cytometer (BD), and data were analyzed using FlowJo software (TreeStar).
Metabolic analyses. The Seahorse XFe96 analyser and Mitostress test kits were used to measure meta-
bolic profiles, according to the manufacturer’s instructions. Briefly, effector or memory phenotype T cells 
(105/well) were transferred to Seahorse assay plates and adhered using a Cell-Tak solution (Corning) in 
complete XF assay medium. Oligomycin (1 μM), FCCP (1.5 μM), and rotenone/antimycin A (0.5 μM) 
were injected using the Mitostress test protocol. Data were collected in Wave software and analyzed using 
GraphPad Prism.
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Western blotting. T cell lysates were prepared in lysis buffer (0.15 M NaCl, 50 mM Tris-HCL, 1% Triton 
X-100, 0.5% n-Dodecyl-b-D-maltoside, protease and phosphatase inhibitors), and Western blotting was 
performed as described previously (36). Membranes were probed with anti-PTPN22 (D6D1H, custom for-
mulation with no carrier protein, Cell Signaling Technology) and ZAP70 (clone 29/ZAP70, BD Bioscienc-
es) mAbs. Secondary antibodies were from Molecular Probes. Signals were detected and quantified using 
a LICOR Imaging System.
Statistics. Statistical analyses were performed using GraphPad Prism. Two-tailed Student’s t tests, with 
Holm-Sidak correction for multiple comparisons where appropriate, or 1- or 2-way ANOVA, with Tukey’s 
multiple comparison test, were applied. For long-term survival experiments, χ2 and log-rank tests were 
applied. P < 0.05 was considered significant. Error bars represent SDs. Numbers of  experimental and/or 
technical replicates are described in figure legends.
Study approval. Protocols using live animals were performed in accordance with a United Kingdom 
Home Office project licence (PPL - PDAD2D507) and the regulations of  the University of  Leeds Animal 
Welfare and Ethics Review Board, which approved these experiments.
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